Antiobesity Market Report 2026

The antiobesity market size has grown strongly in recent years. It will grow from $4.1 billion in 2025 to $4.47 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to rising global obesity rates, limited success of lifestyle-only interventions, availability of appetite suppressants, growing metabolic disorder burden, physician-led weight management.

The antiobesity market size is expected to see rapid growth in the next few years. It will grow to $6.56 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to increasing prevalence of diabetes and obesity, innovation in hormone-based drugs, expansion of reimbursement coverage, rising obesity awareness, demand for sustainable weight loss solutions. Major trends in the forecast period include rapid adoption of glp-1 based therapies, growing preference for prescription weight loss drugs, increasing use of combination antiobesity therapies, rising focus on long-term weight management, expansion of obesity treatment access.

The increasing prevalence of obesity is expected to drive the growth of the anti-obesity drugs market in the coming years. Obesity is a chronic metabolic disorder marked by excessive accumulation of body fat, which elevates the risk of severe health complications such as diabetes, cardiovascular diseases, osteoarthritis, and certain types of cancer. The rise in obesity prevalence is largely attributed to higher consumption of ultra-processed foods rich in sugars, unhealthy fats, and refined carbohydrates, along with sedentary lifestyles that limit physical activity. This increase in obesity cases is creating a greater demand for effective anti-obesity medical treatments, supportive weight management therapies, and long-term interventions to reduce associated health risks and improve patient outcomes. For example, in March 2024, the World Obesity Federation, a UK-based organization dedicated to obesity research and advocacy, projected that by 2035, 79% of adults and 88% of children with overweight and obesity will reside in low- and middle-income countries. Consequently, the rising prevalence of obesity is propelling the growth of the anti-obesity drugs market.

Major companies in the anti-obesity market are emphasizing product innovation and formulation, such as dual glucose‑dependent insulinotropic peptide (GIP) receptor agonists, to offer more effective weight loss, enhanced metabolic outcomes, and improved tolerability. These therapies utilize synergistic mechanisms on appetite suppression, insulin sensitivity, and energy expenditure to provide superior efficacy compared to earlier-generation GLP‑1-only treatments. For example, in December 2024, Eli Lilly, a US-based pharmaceutical company, obtained FDA approval for Zepbound (tirzepatide), making it the first and only prescription dual GIP/GLP-1 agonist approved for chronic weight management. Tirzepatide has shown strong weight-loss efficacy, with phase 3 trial participants achieving substantial reductions in body weight. With this new indication, Zepbound is expected to strengthen Lilly’s leadership in the precision obesity therapy field, addressing the rising demand for long-acting, high-efficacy treatments.

In August 2023, Eli Lilly, a US-based pharmaceutical company, acquired Versanis Bio for an undisclosed amount. Through this acquisition, Eli Lilly intends to enhance its anti-obesity drug portfolio by incorporating Versanis Bio’s innovative therapies that target metabolic and weight-management pathways, facilitating the development of next-generation treatments for obesity and related metabolic disorders. Versanis Bio, a US-based biotechnology company, focuses on the development of novel therapeutics for obesity and metabolic diseases and has a strong track record in preclinical and early clinical research.

Major companies operating in the antiobesity market are Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd.

North America was the largest region in the anti-obesity market in 2025. Middle East is expected to be the fastest-growing region in the antiobesity market. The regions covered in the antiobesity market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antiobesity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased the cost of imported APIs used in antiobesity drug manufacturing and formulation activities. These impacts are most pronounced in North America and Europe, where many metabolic drug producers rely on global api supply networks. Rising tariff related input costs have placed pressure on production economics and pricing strategies for weight management therapies. This has influenced procurement planning and market access decisions among pharmaceutical companies. However, tariffs are also encouraging domestic manufacturing of metabolic drugs, localized api production, and stronger regional pharmaceutical supply chains over the long term.

The antiobesity market research report is one of a series of new reports that provides antiobesity market statistics, including antiobesity industry global market size, regional shares, competitors with a antiobesity market share, detailed antiobesity market segments, market trends and opportunities, and any further data you may need to thrive in the antiobesity industry. This antiobesity market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-obesity drugs are medications used to reduce or manage a patient’s weight. These drugs work by targeting one of the body’s fundamental functions - weight control - either by influencing appetite or affecting calorie absorption. Maintaining a healthy diet and engaging in regular exercise remain the primary therapeutic strategies for individuals who are overweight or obese.

The primary categories of drugs used in anti-obesity treatment are those that act peripherally and those that act centrally. Anti-obesity medications with a peripheral mechanism aid in weight loss without affecting the brain or suppressing appetite. They inhibit pancreatic lipase and prevent the breakdown of fats in the gastrointestinal tract, reducing fat absorption through the intestines. These drugs are available as prescription medications (Rx) and over-the-counter (OTC) products and include a variety of options such as monotherapies and combination therapies.

The anti-obesity market consists of sales of liraglutide, semaglutide, naltrexone-bupropion, and orlistat. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.